A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
Published Online: 2011-05-19
Journal: Investigational New Drugs•Publisher: Springer Science and Business Media LLC
Authors: Constanta Timcheva•David Robert Spigel•G. Pover•György Bodoky•N. C. Tebbutt•Phillip Joseph La Stella•Tudor Eliade Ciuleanu
